MDXH
MDxHealth SA ADRNASDAQHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$104.78M
P/E Ratio
—
EPS
$-0.67
Beta
-537543.56
52W High
$5.33
52W Low
$1.67
50-Day MA
$2.83
200-Day MA
$3.40
Dividend Yield
—
Profit Margin
-31.10%
Forward P/E
27.70
PEG Ratio
—
About MDxHealth SA ADR
MDxHealth SA is an innovative biotechnology company specializing in precision diagnostics that significantly enhance cancer management, with a primary focus on prostate and bladder cancers. Its leading product, ConfirmMDx for Prostate Cancer, has gained recognition for its clinical effectiveness and substantial market traction. As the shift towards personalized medicine accelerates and the demand for targeted cancer therapies grows, MDxHealth is strategically positioned to broaden its portfolio of cutting-edge diagnostic solutions, addressing critical unmet needs in oncology while aiming to improve patient outcomes and drive sustainable growth.
Fundamentals
| Revenue (TTM) | $107.88M |
| Gross Profit (TTM) | $69.63M |
| EBITDA | $-7.06M |
| Operating Margin | -17.80% |
| Return on Equity | -2440.00% |
| Return on Assets | -5.90% |
| Revenue/Share (TTM) | $2.16 |
| Book Value | $-0.23 |
| Price-to-Book | 23.64 |
| Price-to-Sales (TTM) | 0.97 |
| EV/Revenue | 1.505 |
| EV/EBITDA | 17.57 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 19.40% |
| Shares Outstanding | $51.37M |
| Float | $35.68M |
| % Insiders | 11.18% |
| % Institutions | 49.78% |
Historical Volatility
HV 10-Day
55.81%
HV 20-Day
56.45%
HV 30-Day
62.13%
HV 60-Day
53.56%
HV Rank
67.1%
Volatility is currently contracting
Analyst Ratings
Consensus ($7.40 target)
6
BuyData last updated: 4/29/2026